| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 1 | Use of benzoin gum to inhibit P-glycoprotein-mediated resistance of pharmaceutical compounds | US973593 | 1998-02-11 | US5916566A | 1999-06-29 | Leslie Z. Benet; Vincent J. Wacher; Reed M. Benet |
| A method for increasing bioavailabilty of an orally administered hydrophobic pharmaceutical compound, which comprises orally administering the pharmaceutical compound to a mammal in need of treatment with the compound concurrently with an essential oil or essential oil component in an amount sufficient to provide bioavailability of the compound in the presence of the essential oil or essential oil component greater than bioavailability of the compound in the absence of the essential oil or essential oil component, wherein the essential oil or essential oil component has an activity of at least 10% inhibition at a concentration 0.01 wt. % or less in an assay that measures reduced conversion of cyclosporine to hydroxylated products using an assay system containing 250 .mu.g rat liver microsomes, 1 .mu.M cyclosporine, and 1 .mu.M reduced nicotinamide adenine dinucleotide phosphate (NADPH) in 1 ml of 0.1 M sodium phosphate buffer, pH 7.4. | ||||||
| 2 | Externally-applied medicine for curing black foot disease | US497169 | 1995-06-30 | US6077512A | 2000-06-20 | Ren-Rong Chen |
| An externally-applied medicine for curing black foot disease comprising a basis part consisting of equal amount of ground, powdered, and mixed clove, frankincense, myrrha, rhizama arisaematis, pinellia, monkshood (root) or kusnezoff monkshood (root), and tuber of bamboo-leaved orchid, and an adjuvant part consisting of equal amount of round, powdered, and mixed borneol, powdered soy bean, borax, coptis root and/or phellodendron amureuse, and sepia aculeata. The medicine is used in such a manner that the powdered basis part is mixed and stirred with tea water until it becomes plaster-like, and the adjuvant part is scattered in dry form onto the wound or swollen area caused by the black foot disease before the plaster-like basis part is applied to the wound or swollen area about 0.5 cm in thickness. The wound is then bandaged and the medicine is renewed once to twice a day until fresh flesh appears in the wound. Thereafter, the medicine is continuously applied but in a dry form until the wound is completely healed. | ||||||
| 3 | Cell proliferator and applications thereof | US947164 | 1997-10-08 | US6010701A | 2000-01-04 | Yumiko Matsukura; Kazuhiko Tokoro |
| A cell proliferator comprising as an active ingredient a distilled residue of an extract obtained by extracting one or more specific plants as raw materials of spicery with one or more solvents selected from the group consisting of water, lower alcohols, polyol type organic solvents, petroleum ether and hexane; a spicery composition comprising the cell proliferator; an external agent for skin comprising the cell proliferator; and a bathing agent comprising the cell proliferator. | ||||||
| 4 | Method of extracting drugs | US38222341 | 1941-03-07 | US2347322A | 1944-04-25 | JACKSON WILLIAM H |
| 5 | Use of essential oils to increase bioavailability of orally administered pharmaceutical compounds | US19936 | 1998-02-06 | US6121234A | 2000-09-19 | Leslie Z. Benet; Vincent J. Wacher; Reed M. Benet |
| A method for increasing bioavailability and reducing inter- and intra-individual variability of an orally administered hydrophobic pharmaceutical compound, which comprises orally coadministering the pharmaceutical compound to a mammal in need of treatment with the compound with an essential oil or essential oil component in an amount sufficient to provide bioavailability of the compound in the presence of the essential oil or essential oil component greater than bioavailability of the compound in the absence of the essential oil or essential oil component, wherein the essential oil or essential oil component has an activity of at least 10% inhibition at a concentration of 0.01 wt. % or less in an assay that measures conversion of cyclosporine to hydroxylated products using an assay system containing 250 .mu.g rat liver microsomes, 1 .mu.M cyclosporine, and 1 mM reduced nicotinamide adenine dinucleotide phosphate (NADPH) in 1 ml of 0.1 M sodium phosphate buffer, pH 7.4. | ||||||
| 6 | Use of odorants to treat male impotence, and article of manufacture therefor | US606544 | 1996-02-23 | US5885614A | 1999-03-23 | Alan R. Hirsch |
| A method is provided for inducing or enhancing penile erection through the delivery of odorants for inhalation. The administration of odorants provides an increase in blood flow to the penis, and a therapeutic aid to stimulate sexual activity and alleviate male vasculogenic impotence. | ||||||
| 7 | Use of essential oils to increase bioavailability of oral pharmaceutical compounds | US478207 | 1995-06-07 | US5716928A | 1998-02-10 | Leslie Z. Benet; Vincent J. Wacher; Reed M. Benet |
| A method for increasing bioavailability and reducing inter- and intra-individual variability of an orally administered hydrophobic pharmaceutical compound, which comprises orally administering the pharmaceutical compound to a mammal in need of treatment with the compound concurrently with an essential oil or essential oil component in an amount sufficient to provide bioavailability of the compound in the presence of the essential oil or essential oil component greater than bioavailability of the compound in the absence of the essential oil or essential oil component, wherein the essential oil or essential oil component has an activity of at least 10% inhibition at a concentration of 0.01 wt. % or less in an assay that measures conversion of cyclosporine to hydroxylated products using an assay system containing 250/.mu.g rat liver microsomes, 1.mu.M cyclosporine, and 1 mM reduced nicotinamide adenine dinucleotide phosphate (NADPH) in 1 ml of 0.1M sodium phosphate buffer, pH 7.4. | ||||||
| 8 | Process for preparation of aloe products products, produced thereby and compositions thereof | US869261 | 1986-06-05 | US4735935A | 1988-04-05 | Bill H. McAnalley |
| Process for producing aloe extracts including the separation of the leaves of the aloe plant into distinct portions. In particular, a first process is described for producing an aloe extract which is substantially free of anthraquinone-rich yellow sap and a second process is described for extracting the active chemical substance in the aloe plant.The active chemical substance in the aloe plant is extracted from aloe leaves and its characteristic properties are described. | ||||||
| 9 | 消炎・消腫・止痛用の漢方薬草組成物の製造方法、及びその応用 | JP2012525842 | 2009-09-01 | JP6039421B2 | 2016-12-07 | ウ,チアン シュン; チョウ,タイ‐チン |
| 10 | 美容的処置のためのハエジゴクの抽出物を含有する組成物 | JP2012551125 | 2011-01-24 | JP5940986B2 | 2016-06-29 | ダールグレン アッティ−ラ; ダールグレン ジョン; ドルジ タシ ヤングゾム; ドルジ シンゲイ; ジエルトセン シェラブ |
| 11 | 皮膚老化の兆候の出現を予防または遅延させる活性薬剤としてのブラソカトレア・マーセラ・コス（Ｂｒａｓｓｏｃａｔｔｌｅｙａ ｍａｒｃｅｌｌａ Ｋｏｓｓ）ラン抽出物の使用 | JP2009058436 | 2009-03-11 | JP5642354B2 | 2014-12-17 | ジャン、ユベール、コシャル; ジャン‐クリストフ、アルシャンボル; クリステル、ラズ; フレデリック、ボンテ |
| 12 | ブラソカトレア・マーセラ・コス（Ｂｒａｓｓｏｃａｔｔｌｅｙａ ｍａｒｃｅｌｌａ Ｋｏｓｓ）のラン抽出物および皮膚脱色素剤としてのその使用 | JP2009058381 | 2009-03-11 | JP5642353B2 | 2014-12-17 | ジャン‐クリストフ、アルシャンボル; ジャン、ユベール、コシャル; クリステル、ラズ; フレデリック、ボンテ |
| 13 | ラン科植物から分離した新規物質、これを含む抽出物、抗酸化剤、抗菌剤、抗癌剤及び抗炎症剤 | JP2010545712 | 2010-07-08 | JPWO2012004875A1 | 2013-09-02 | 和子 吉川; 敏弘 橋本; 千裕 馬場; 洋 今川; 森田 博史; 博史 森田; 賀奈子 井関; 幸子 河野 |
| 【課題】副作用を起こすことなく、有効な抗酸化作用を有する抗酸化剤を提供する。【解決手段】下記式(1)で示される新規物質。 | ||||||
| 14 | ラン科植物から得られる抽出物およびその製造方法、ならびにラン科植物から得られる抽出物を含有する皮膚外用剤 | JP2009543295 | 2009-03-27 | JPWO2009139231A1 | 2011-09-15 | 晶子 佐々木; 将和 川口; 綾香 桧物 |
| 本発明は、ラン科オドントグロッサム属の植物、またはオドントグロッサム属とコクリオダ属の交配属由来の植物から得られる抽出物、該抽出物の製造方法、および該抽出物を含有する皮膚外用剤に関する。 | ||||||
| 15 | Brassocattleya marcella koss orchid extract and use thereof as skin depigmentation agent | JP2009058381 | 2009-03-11 | JP2009221200A | 2009-10-01 | ARCHAMBAULT JEAN-CHRISTOPHE; CAUCHARD JEAN HUBERT; LAZOU KRISTELL; BONTE FREDERIC |
| <P>PROBLEM TO BE SOLVED: To provide a composition such as a cosmetic composition intended to lighten the skin coloring or to improve the uniformity of skin blood color, or to correct or attenuate skin spots or hyperpigmented skin areas. <P>SOLUTION: An orchid extract obtained by extracting at least a part of Brassocattleya marcella Koss variety with a polar solvent or a mixture of polar solvents is used as a skin depigmentation agent. <P>COPYRIGHT: (C)2010,JPO&INPIT | ||||||
| 16 | Antimicrobial composition comprising a synergistic combination of essential oils and / or its components as quaternary ammonium compounds | JP2006520288 | 2004-07-15 | JP2007534620A | 2007-11-29 | ガオンカール，トルプティ; カラオス，ラウサーピナ; シンター，ミリンド，エス．; モダック，シャンタ，エム． |
| 本発明は、増強された抗菌効果を示す第4級アンモニウム化合物および精油またはその個々の構成要素を含む組成物に関する。 このような組合せは、皮膚または粘膜に塗布するためにローション、ゲル、クリーム、ソープなどに含まれうる。 本発明は、相乗的な抗菌効果が精油またはその個々の構成要素と低濃度の第4級アンモニウム化合物を組み合わせることによって得られるという観察に少なくとも一部基づく。 | ||||||
| 17 | Use of plant extract of anoectochilus formosanus and fraction originating from the same as galenicals or dietary supplement for chemical defense or treatment of human malignant lesion | JP2003274295 | 2003-07-14 | JP2004035568A | 2004-02-05 | SHYUR LIE-FEN; YANG NING-SUN; KANG PEI-LING; SUN SHOW-JANE; WANG SHENG-YANG |
| <P>PROBLEM TO BE SOLVED: To provide a medicinally active extract and fraction, and a method for preparing the same by extracting and fractionating components from the tissues of a plant constitution part of the Anoectochilus family. <P>SOLUTION: The medicinally active extract and fraction are useful for prevention or suppression of tumor growth. Dosage of the extract of the herby plant to human is carried out by an oral delivery (liquid drinking) of a partially purified plant extract, an intratumoral (subcuticular) injection, an intraperitoneal injection, a topical application and an intervenous injection. <P>COPYRIGHT: (C)2004,JPO | ||||||
| 18 | Cancer drug formulations and methods of using natural plant essential oil along with the signaling modulators | JP2000586349 | 1999-12-07 | JP2002531513A | 2002-09-24 | エッサム イー． エナン; スティーブン エム． ベセッテ |
| Pharmaceutical compositions containing plant essential oils, natural or synthetic, or mixtures or derivatives thereof, for the prevention and treatment of soft tissue cancer in mammals. | ||||||
| 19 | Cancer drug formulations and methods of using the signaling modulators and natural plant essential oils | JP2000586347 | 1999-12-07 | JP2002531511A | 2002-09-24 | エッサム イー． エナン; スティーブン エム． ベセッテ |
| Pharmaceutical compositions containing plant essential oils, natural or synthetic, or mixtures or derivatives thereof, for the prevention and treatment of soft tissue cancer in mammals. | ||||||
| 20 | Use of essential oils to enhance the bioavailability of oral pharmacological compounds | JP50189096 | 1996-06-07 | JPH11507356A | 1999-06-29 | ジェイ． ウォッチャー，ビンセント; リード，エム． ベネット; ゼット． ベネット，レスリー |
| (57)【要約】 経口投与した疎水性薬理化合物の生物有用性を高めるための方法であって：前記化合物による処置を必要とする哺乳動物にエッセンシャルオイル又はエッセンシャルオイル成分を、前記エッセンシャルオイル又はエッセンシャルオイル成分の非存在下での前記化合物の生物有用性よりも高い前記エッセンシャルオイル又はエッセンシャルオイル成分の存在下での前記化合物の生物有用性を供するのに十分な量で前記化合物と同時に経口投与することを含んで成り、ここで前記エッセンシャルオイル又はエッセンシャル成分は、100μｌの 0.1Ｍのリン酸ナトリウムバッファー、pH 7.4の中の 100μｇのヒト肝臓又は腸内細胞ミクロソーム、25μＭのシクロスポリン、及び NADPH再生系を含むアッセイ系を利用してシクロスポリンのヒドロキシル化生成物に至る還元変換を測定するアッセイにおいて、0.001重量％以下の濃度において10％以上の阻害活性を有するものである、前記方法。 | ||||||
QQ群二维码
意见反馈
意见反馈